Journal ArticleDOI
Challenges and Opportunities for COVID-19 Vaccines in Patients with Cancer.
Nicole M. Kuderer,Joshua A. Hill,Joshua A. Hill,Paul A. Carpenter,Paul A. Carpenter,Gary H. Lyman,Gary H. Lyman +6 more
TLDR
Based on a review of the available data on the efficacy and safety of the approved and forthcoming vaccines in patients with cancer, the authors recommended that most patients should receive the recommended dose and schedule of one of the COVID-19 vaccines when available.Abstract:
Given the rapidly expanding global spread of the SARS-Co-V-2 virus and the expanding number of individuals with the serious and potentially fatal illness, COVID-19, there is an urgent need for safe and effective vaccines Based on compelling evidence that patients with cancer are at increased risk for greater morbidity and mortality with COVID-19, several professional organizations have provided early guidance on the role of COVID-19 vaccines in patients with malignant disease In this commentary we review the available data on the efficacy and safety of the approved and forthcoming vaccines in patients with cancer Based on a review of the totality of available evidence, we recommend that most patients with cancer should receive the recommended dose and schedule of one of the COVID-19 vaccines when available We encourage industry, regulators and professional research organizations to carefully track the efficacy and safety of COVID-19 vaccination in patients with cancer in the real world setting and routinely report unanticipated adverse events and signs of loss of efficacy Particular attention is needed for patients on active cancer therapy to carefully evaluate efficacy and safety in relationship to the timing of vaccination relative to that of active cancer treatment and immunosuppressionread more
Citations
More filters
Journal ArticleDOI
Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy.
Mona Ariamanesh,Pejman Porouhan,Babak PeyroShabany,Danial Fazilat-Panah,Mansoureh Dehghani,Maryam Nabavifard,Farbod Hatami,Mohammad Fereidouni,James S Welsh,Seyed Alireza Javadinia +9 more
TL;DR: In this paper, the safety and immunogenicity of the inactivated SARS-CoV-2 vaccine in cancer patients were evaluated and the results confirmed the short-term efficacy of inactivated vaccine in patients with malignancies.
Journal ArticleDOI
Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study
TL;DR: In this paper , the authors conducted a population-based test-negative case-control study of the UK Coronavirus Cancer Evaluation Project (UKCCEP), and extracted data from the UKCCEP registry on all SARS-CoV-2 PCR test results (from the Second Generation Surveillance System), vaccination records from the National Immunisation Management Service, patient demographics, and cancer records from England, UK, from Dec 8, 2020, to Oct 15, 2021.
Journal ArticleDOI
Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study
Lennard Y W Lee,Thomas Starkey,Mariana Ionescu,M.A. Little,Michael J. Tilby,Arvind Tripathy,H Mckenzie,Youssra Al-Hajji,M. Barnard,Liza Benny,Alexander Burnett,Emma Cattell,Jackie Charman,James J. Clark,Sam Khan,Qamar Ghafoor,George Illsley,Catherine Harper-Wynne,Rosie Hattersley,Alvin J.X. Lee,Pauline Leonard,Justin Liu,M. Pang,Jennifer Pascoe,James R. Platt,Vanessa Potter,A. D. Randle,Anne Rigg,Timothy Robinson,Tom Roques,Rene Roux,Stefan Rozmanowski,Mark Tuthill,Isabella Watts,Sarah R. Williams,Timothy Iveson,Siow Ming Lee,Gary Middleton,Mark R. Middleton,Andrew Protheroe,Matthew Fittall,Tom Fowler,Peter Johnson,Emma Kinloch,Emily Lam,Gillian Murphy,Malcolm Rhodes,Kate Robinson +47 more
TL;DR: COVID-19 vaccination is effective for individuals with cancer, conferring varying levels of protection against breakthrough infections, however, vaccine effectiveness is lower in patients with cancer than in the general population.
Journal ArticleDOI
Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation
TL;DR: In this paper , the authors showed that patients with lung cancer are especially vulnerable to coronavirus disease 2019 (COVID-19) with a greater than sevenfold higher rate of becoming infected with SARS-CoV-2, a higher hospitalization rate with high complication rates, and an estimated case fatality rate of more than 30%.
Journal ArticleDOI
Impact of corona-phobia on attitudes and acceptance towards COVID-19 vaccine among cancer patients: a single-center study.
Dilek Erdem,Irem Karaman +1 more
TL;DR: In this article, a prospective cross-sectional descriptive study was conducted with 300 adult patients using a validated COVID-19 phobia scale (C19P-S) and related survey to determine the factors affecting vaccine acceptance between May-June 2021.
References
More filters
Journal ArticleDOI
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Fernando P. Polack,Stephen J. Thomas,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Edson D. Moreira,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Satrajit Roychoudhury,Kenneth Koury,Ping Li,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +28 more
TL;DR: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.
Journal ArticleDOI
First Case of 2019 Novel Coronavirus in the United States.
Michelle Holshue,Chas DeBolt,Scott Lindquist,Kathy H Lofy,John Wiesman,Hollianne Bruce,Christopher Spitters,Keith M. Marzilli Ericson,Sara Wilkerson,Ahmet Tural,George Diaz,Amanda C. Cohn,LeAnne Fox,Anita Patel,Susan I. Gerber,Lindsay Kim,Suxiang Tong,Xiaoyan Lu,Steve Lindstrom,Mark A. Pallansch,William C. Weldon,Holly M. Biggs,Timothy M. Uyeki,Satish K. Pillai +23 more
TL;DR: This case highlights the importance of close coordination between clinicians and public health authorities at the local, state, and federal levels, as well as the need for rapid dissemination of clinical information related to the care of patients with this emerging infection.
Journal ArticleDOI
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.
Wenhua Liang,Wei-jie Guan,Ruchong Chen,Wei Wang,Jianfu Li,Ke Xu,Caichen Li,Qing Ai,Weixiang Lu,Hengrui Liang,Shiyue Li,Jianxing He +11 more
Journal ArticleDOI
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
Lindsey R. Baden,Hana M. El Sahly,Brandon Essink,Karen L. Kotloff,Sharon E. Frey,Rick Novak,David Diemert,Stephen A. Spector,Nadine Rouphael,C. Buddy Creech,John W McGettigan,Shishir Khetan,Nathan Segall,Joel Solis,Adam Brosz,Carlos Fierro,Howard J. Schwartz,Kathleen M. Neuzil,Lawrence Corey,Peter B. Gilbert,Holly Janes,Dean Follmann,Mary A. Marovich,John R. Mascola,Laura Polakowski,Julie E. Ledgerwood,Barney S. Graham,Hamilton Bennett,Rolando Pajon,Conor Knightly,Brett Leav,Weiping Deng,Honghong Zhou,Shu Liang Han,Melanie Ivarsson,Jacqueline Miller,Tal Z Zaks +36 more
TL;DR: The mRNA-1273 vaccine as discussed by the authors is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19.
Journal ArticleDOI
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
TL;DR: The wide range of immune-related adverse effects associated with immune checkpoint blockade can complicate this effective therapy and limit its use in patients with cancer.